PT  - JOURNAL ARTICLE
AU  - Conlin, Christopher C
AU  - Karunamuni, Roshan
AU  - Hussain, Troy S
AU  - Zhong, Allison Y
AU  - Kallis, Karoline
AU  - Do, Deondre D
AU  - Lui, Asona J
AU  - Mani, Garnier
AU  - Ollison, Courtney
AU  - Domingo, Mariluz Rojo
AU  - Shabaik, Ahmed
AU  - Kane, Christopher J
AU  - Bagrodia, Aditya
AU  - McKay, Rana R
AU  - Kuperman, Joshua M
AU  - Rakow-Penner, Rebecca
AU  - Hahn, Michael E
AU  - Dale, Anders M
AU  - Seibert, Tyler M
TI  - Background prostate tissue is quantitatively abnormal on MRI in patients with clinically significant prostate cancer
AID  - 10.1101/2022.10.12.22280855
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2022.10.12.22280855
4099  - http://medrxiv.org/content/early/2023/02/21/2022.10.12.22280855.short
4100  - http://medrxiv.org/content/early/2023/02/21/2022.10.12.22280855.full
AB  - Background T2-weighted MRI is standard for detecting clinically significant prostate cancer (csPCa) by identifying visible lesions that stand out from the background prostate.Purpose To determine whether patients with csPCa have abnormal T2-weighted signal in non-lesion, background prostate tissue (BP).Methods This retrospective study included two patient cohorts who underwent 3T MRI examination for suspected csPCa. Median (urine-normalized) T2-weighted signal was computed for BP and compared between patients with and without csPCa. csPCa discrimination performance of T2-weighted BP signal was evaluated using area under receiver operating characteristic curves (AUC). T2 and S0 (a proxy for proton density) were computed and compared between patients with and without csPCa. T2 was also recomputed using larger buffers around csPCa lesions. csPCa discrimination performance was compared between two predictors: Restriction Spectrum Imaging (RSI) C1 and RSI C1 normalized by global prostate median T2-weighted signal.Results Cohort 1: 46 patients (age: 64±10 years). Cohort 2: 151 patients (65±8 years). Urine-normalized T2-weighted signal was systematically lower in BP of subjects with csPCa (p≤0.034) and indicated the presence of cancer (cohort 1: AUC=0.80; cohort 2: AUC=0.68). BP T2 was significantly lower in csPCa patients (p≤0.011), while S0 was not (p≥0.30). BP T2 measurements were stable to within 5% with buffers from 0 to 30 mm around visible lesions. csPCa discrimination improved with incorporation of BP T2-weighted signal (cohort 1: AUC=0.72 for RSI C1 alone, versus 0.81 with BP T2-weighted signal; cohort 2: AUC=0.63 versus 0.76).Conclusion Lower T2-weighted signal in BP suggests the presence of csPCa.Competing Interest StatementAMD is a Founder of and holds equity in CorTechs Labs, Inc, and serves on its Scientific Advisory Board. He is a member of the Scientific Advisory Board of Human Longevity, Inc. and receives funding through research agreements with General Electric Healthcare. RRP is a consultant for Human Longevity, Inc. She also receives funding through research grants from GE Healthcare and Imagine Scientific to the University of California San Diego; she has an equity interest in CorTechs Labs, Inc. and serves on its Scientific Advisory Board. She also has equity interest in CureMetrix. TMS reports honoraria from Multimodal Imaging Services Corporation, Varian Medical Systems, and WebMD; he has an equity interest in CorTechs Labs, Inc. and serves on its Scientific Advisory Board. These companies might potentially benefit from the research results. The terms of the above arrangements have been reviewed and approved by the University of California San Diego in accordance with its conflict-of-interest policies.Funding StatementThis work was funded by the Prostate Cancer Foundation, the American Society for Radiation Oncology, and the National Institutes of Health (#K08EB026503, #UL1TR000100)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of University of California San Diego gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the corresponding author